Berlin, Sep 4 (AP) German pharmaceutical company CureVac says it is receiving a further 252 million euros (USD 298 million) to develop a coronavirus vaccine.

The company says its request for additional funding has been approved by Germany's Ministry for Education and Research, provided certain milestones are reached.

Also Read | COVID-19 Vaccine Update: Russia in Dialogue With India For Localised Production of ‘Sputnik V’.

Germany's state-owned KfW bank has already taken a 23% stake in CureVac for 300 million euros.

The company launched an initial public offering of shares, but its main shareholder remains Dietmar Hopp, the co-founder of German software giant SAP.

Also Read | Charlie Hebdo’s Republication of Cartoons of Prophet Muhammad A ‘Provocation’, is ‘Absolutely Unacceptable’, Says Iran.

CureVac is among a small number of companies that aim to develop a COVID-19 vaccine using mRNA technology that experts say could allow rapid inoculation on a larger scale than traditional forms of vaccination. (AP)

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)